Use of dienogest over 53 weeks for the treatment of endometriosis

Sugimoto K, Kouhei Sugimoto, Chie Nagata, Nagata C, Hayashi H, Hiroshi Hayashi, Yanagida S, Satoshi Yanagida, Okamoto A, Aikou Okamoto
Journal of Obstetrics and Gynaecology Research · 2015 · vol. 41(12) , pp. 1921–1926 · doi:10.1111/jog.12811 · PMID:26369271 · W2123519165
Other OA: closed CC0 ⤵ 50 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This retrospective study found dienogest treatment for 53 weeks reduced adenomyosis and ovarian cysts in endometriosis patients, with atypical genital bleeding being the most common side effect.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: To evaluate the efficacy and adverse effects of Dienogest (DNG) over 53 weeks for the treatment of endometriosis. METHODS: DNG was administered to 75 patients with endometriosis over a period of 53 weeks. Medical charts were retrospectively examined on the efficacy and side effects. Reduction rates of ovarian chocolate cyst, adenomyosis and changes in serum estradiol and cancer antigen 125 concentration were measured. Adverse effects, patient evaluation of their symptoms and willingness to continue taking DNG were assessed by a questionnaire. RESULTS: The median duration of treatment was 87 weeks, with the longest follow-up duration being 120 weeks. Ovarian chocolate cysts were initially reduced; however, upon cessation of DNG treatment, an increase in size was observed. Adenomyosis lesions were reduced to some extent after 53 weeks of DNG treatment. In terms of adverse events, more than 60% (61.3%, 46/75) of patients experienced atypical genital bleeding. However, this did not prove to be a cause of discontinuation. We ceased DNG treatment in two cases because of lower abdominal pain and shoulder discomfort. CONCLUSIONS: Long term DNG treatment beyond one year for endometriosis proved to be effective and safe. Ovarian chocolate cysts were markedly reduced by short-term use of DNG, while a longer duration was required to reduce the size of adenomyosis. The decision regarding the choice of therapy lies with the individual clinician, considering a balance of efficacy with expense and adverse effects.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Endometriosis Nandrolone Adult Adult CA-125 Antigen CA-125 Antigen CA-125 Antigen Endometriosis Endometriosis Estradiol Estradiol Estradiol Female Female Humans Humans Membrane Proteins Membrane Proteins Membrane Proteins Middle Aged

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (15)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:16:21.477467+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK